Business Context and Reporting Period
This Form 8-K Current Report was filed by Pliant Therapeutics, Inc. on December 10, 2025. The filing discloses a change in executive leadership within the biotechnology company, which is incorporated in Delaware and trades on The Nasdaq Stock Market under the symbol PLRX.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the appointment of Minnie Kuo as Chief Operating Officer (COO), effective December 10, 2025. Ms. Kuo previously served as the Company's Chief Development Officer since September 2023. She brings over 20 years of experience in clinical development from prior roles at Vir Biotechnology, Nektar Therapeutics, Gilead Sciences, and Roche/Genentech.
Guidance, Outlook, and Management Commentary
The filing does not contain updated financial guidance, strategic outlook, or general management commentary regarding the company's pipeline or market position. Regarding the executive appointment, the Company stated that Ms. Kuo was not provided with any additional compensation at the time of her appointment. No risks, contingencies, or unusual items were disclosed in this specific report.
Investor Verification Checklist
- Verify the effective date of Minnie Kuo's appointment as COO (December 10, 2025).
- Confirm that no additional compensation was granted to Ms. Kuo upon this promotion.
- Review Ms. Kuo's prior tenure as Chief Development Officer starting in September 2023.
- Note that this filing contains no financial data; refer to recent 10-K or 10-Q filings for financial health metrics.